» Articles » PMID: 9364062

Delayed Reduction of Ischemic Brain Injury and Neurological Deficits in Mice Lacking the Inducible Nitric Oxide Synthase Gene

Overview
Journal J Neurosci
Specialty Neurology
Date 1997 Dec 31
PMID 9364062
Citations 183
Authors
Affiliations
Soon will be listed here.
Abstract

Inducible nitric oxide synthase (iNOS), an enzyme that produces toxic amounts of nitric oxide, is expressed in a number of brain pathologies, including cerebral ischemia. We used mice with a null mutation of the iNOS gene to study the role of iNOS in ischemic brain damage. Focal cerebral ischemia was produced by occlusion of the middle cerebral artery (MCA). In wild-type mice, iNOS mRNA expression in the post-ischemic brain begun between 24 and 48 hr peaked at 96 hr and subsided 7 d after MCA occlusion. iNOS mRNA induction was associated with expression of iNOS protein and enzymatic activity. In contrast, mice lacking the iNOS gene did not express iNOS message or protein after MCA occlusion. The infarct and the motor deficits produced by MCA occlusion were smaller in iNOS knockouts than in wild-type mice (p < 0.05). Such reduction in ischemic damage and neurological deficits was observed 96 hr after ischemia but not at 24 hr, when iNOS is not yet expressed in wild-type mice. The decreased susceptibility to cerebral ischemia in iNOS knockouts could not be attributed to differences in the degree of ischemia or vascular reactivity between wild-type and knockout mice. These findings indicate that iNOS expression is one of the factors contributing to the expansion of the brain damage that occurs in the post-ischemic period. iNOS inhibition may provide a novel therapeutic strategy targeted specifically at the secondary progression of ischemic brain injury.

Citing Articles

Apelin/APJ system: a novel promising target for anti-oxidative stress in stroke.

Xu W, Yan J, Travis Z, Lenahan C, Gao L, Wu H Front Pharmacol. 2025; 15:1352927.

PMID: 39881878 PMC: 11775478. DOI: 10.3389/fphar.2024.1352927.


The Neural Palette of Heme: Altered Heme Homeostasis Underlies Defective Neurotransmission, Increased Oxidative Stress, and Disease Pathogenesis.

Soladogun A, Zhang L Antioxidants (Basel). 2025; 13(12.

PMID: 39765770 PMC: 11672823. DOI: 10.3390/antiox13121441.


SDMA as a marker and mediator in cerebrovascular disease.

Riddell A, Flynn A, Bergugnat H, Dowsett L, Miller A Clin Sci (Lond). 2024; 138(20):1305-1323.

PMID: 39391895 PMC: 11479986. DOI: 10.1042/CS20241021.


The Influence of Oxidative Stress Markers in Patients with Ischemic Stroke.

Pawluk H, Tafelska-Kaczmarek A, Soponska M, Porzych M, Modrzejewska M, Pawluk M Biomolecules. 2024; 14(9).

PMID: 39334896 PMC: 11430825. DOI: 10.3390/biom14091130.


N, N-Dimethyltryptamine, a natural hallucinogen, ameliorates Alzheimer's disease by restoring neuronal Sigma-1 receptor-mediated endoplasmic reticulum-mitochondria crosstalk.

Cheng D, Lei Z, Chu K, Lam O, Chiang C, Zhang Z Alzheimers Res Ther. 2024; 16(1):95.

PMID: 38693554 PMC: 11061967. DOI: 10.1186/s13195-024-01462-3.


References
1.
Vodovotz Y, Lucia M, Flanders K, Chesler L, Xie Q, Smith T . Inducible nitric oxide synthase in tangle-bearing neurons of patients with Alzheimer's disease. J Exp Med. 1996; 184(4):1425-33. PMC: 2192831. DOI: 10.1084/jem.184.4.1425. View

2.
Ross M, Iadecola C . Nitric oxide synthase expression in cerebral ischemia: neurochemical, immunocytochemical, and molecular approaches. Methods Enzymol. 1996; 269:408-26. DOI: 10.1016/s0076-6879(96)69042-9. View

3.
MacMicking J, Nathan C, Hom G, Chartrain N, Fletcher D, Trumbauer M . Altered responses to bacterial infection and endotoxic shock in mice lacking inducible nitric oxide synthase. Cell. 1995; 81(4):641-50. DOI: 10.1016/0092-8674(95)90085-3. View

4.
Siesjo B . Calcium-mediated processes in neuronal degeneration. Ann N Y Acad Sci. 1994; 747:140-61. DOI: 10.1111/j.1749-6632.1994.tb44406.x. View

5.
Astrup J, Symon L, Branston N, Lassen N . Cortical evoked potential and extracellular K+ and H+ at critical levels of brain ischemia. Stroke. 1977; 8(1):51-7. DOI: 10.1161/01.str.8.1.51. View